SCI Abstract

search
The evolving landscape of obesity pharmacotherapy
The evolving landscape of obesity pharmacotherapy
Obesity is a chronic, relapsing disease driven by complex interactions between genetic, environmental, neuroendocrine and ...
Autophagy modulation in cancer
Autophagy modulation in cancer
Autophagy is a highly conserved, finely regulated and lysosome-dependent biological process through which eukaryotic cells...
Realizing the potential of agonistic antibody immunotherapy
Realizing the potential of agonistic antibody immunotherapy
Agonistic antibodies mimic the activities of native ligands by initiating signalling by the receptors they target. As stim...
Twenty years of induced pluripotent stem cells
Twenty years of induced pluripotent stem cells
Nobel laureate Shinya Yamanaka discusses the therapeutic and drug discovery applications for induced pluripotent stem cells.
Targeting claudins in cancer
Targeting claudins in cancer
Epithelial-derived malignancies account for the majority of human tumours and present considerable treatment challenges ow...
A guide to effective drug development through nonprofit models
Patient organizations are reshaping rare disease drug development where conventional systems falter by integrating patient...
A new European platform for advancing regulatory science research
Launching in 2025, the European Platform for Regulatory Science Research will bring together academia, regulators and othe...
Approvals by the China NMPA in 2024
Approvals by the China NMPA in 2024
Discover the world’s best science and medicine | Nature.com
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
Scholar Rock’s myostatin blocker has shown its efficacy in spinal muscular atrophy, and the 28-year-old myostatin field is...
Can large, simple trials bring drug developers back to common diseases?
Can large, simple trials bring drug developers back to common diseases?
Clinical trials for common diseases can be done much more cheaply, says Martin Landray, a physician and epidemiologist at ...
MYC in cancer: from undruggable target to clinical trials
MYC in cancer: from undruggable target to clinical trials
MYC is among the most infamous oncogenes in cancer. A notable feature that distinguishes it from other common oncogenes is...
Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR
Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR
Quantitative structure–activity relationship (QSAR) modelling, an approach that was introduced 60 years ago, is wide...
Extracellular targeted protein degradation: an emerging modality for drug discovery
Extracellular targeted protein degradation: an emerging modality for drug discovery
Targeted protein degradation (TPD) has emerged in the past decade as a major new drug modality to remove intracellular pro...
Top product forecasts for 2024
Discover the world’s best science and medicine | Nature.com
A decade of HCV drugs
A decade of HCV drugs
Discover the world’s best science and medicine | Nature.com
tRNA therapeutics for genetic diseases
tRNA therapeutics for genetic diseases
Transfer RNAs (tRNAs) have a crucial role in protein synthesis, and in recent years, their therapeutic potential for the t...
CAAR T cells to treat encephalitis
Discover the world’s best science and medicine | Nature.com
A safer polyene antifungal
Discover the world’s best science and medicine | Nature.com